Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDWD MediWound	$17.60 +1.2%	$19.29	$14.14 ▼ $22.50	$187.95M	0.21	75,790 shs	79,455 shs
NLTX Neoleukin Therapeutics	$19.75 +0.7%	$20.30	$2.03 ▼ $14.36	$32.80M	1.11	50,104 shs	51,034 shs
PRLD Prelude Therapeutics	$1.24 +12.7%	$0.87	$0.61 ▼ $5.95	$62.26M	1.22	171,541 shs	486,756 shs
RAPT Rapt Therapeutics	$11.31 +5.5%	$9.91	$5.67 ▼ $26.56	$177.29M	0.01	104,799 shs	34,525 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDWD MediWound	+1.21%	-2.76%	-16.19%	-13.60%	-6.08%
NLTX Neoleukin Therapeutics	+0.20%	-2.23%	-11.59%	+14.29%	-44.89%
PRLD Prelude Therapeutics	+12.73%	+42.53%	+36.26%	+39.92%	-76.87%
RAPT Rapt Therapeutics	+5.50%	-3.66%	-18.87%	+14.94%	-43.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MDWD MediWound	1.5012 of 5 stars	3.4	1.0	0.0	0.0	0.9	0.8	0.6
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	2.9166 of 5 stars	3.5	3.0	0.0	0.0	1.1	3.3	0.6
RAPT Rapt Therapeutics	4.5859 of 5 stars	4.3	3.0	0.0	4.2	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MDWD MediWound	2.80	Moderate Buy	$32.25	83.24% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
PRLD Prelude Therapeutics	3.00	Buy	$4.00	222.58% Upside
RAPT Rapt Therapeutics	2.57	Moderate Buy	$21.57	90.73% Upside

Current Analyst Ratings Breakdown

Latest PRLD, MDWD, RAPT, and NLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	MDWD MediWound	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$4.00 ➝ $3.00
8/12/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/8/2025	RAPT Rapt Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $38.00
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MDWD MediWound	$20.22M	9.41	N/A	N/A	$1.86 per share	9.46
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
PRLD Prelude Therapeutics	$7M	10.03	N/A	N/A	$1.34 per share	0.93
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	$9.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MDWD MediWound	-$30.22M	-$2.64	N/A	N/A	N/A	-142.18%	-96.71%	-39.73%	N/A
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
PRLD Prelude Therapeutics	-$127.17M	-$1.64	N/A	N/A	N/A	N/A	-106.50%	-79.07%	11/5/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$14.17	N/A	N/A	N/A	N/A	-67.92%	-59.59%	11/11/2025 (Estimated)

Latest PRLD, MDWD, RAPT, and NLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MDWD MediWound	-$0.55	-$1.23	-$0.68	-$1.23	$5.68 million	$5.71 million
8/14/2025	Q2 2025	PRLD Prelude Therapeutics	-$0.45	-$0.41	+$0.04	-$0.41	N/A	N/A
8/7/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.61	-$0.65	-$0.04	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MDWD MediWound	N/A	1.48	1.99
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
PRLD Prelude Therapeutics	N/A	3.68	5.18
RAPT Rapt Therapeutics	N/A	13.25	13.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MDWD MediWound	46.83%
NLTX Neoleukin Therapeutics	52.37%
PRLD Prelude Therapeutics	79.72%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
MDWD MediWound	9.20%
NLTX Neoleukin Therapeutics	1.58%
PRLD Prelude Therapeutics	63.90%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
PRLD Prelude Therapeutics	120	56.60 million	20.43 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

PRLD, MDWD, RAPT, and NLTX Headlines

Recent News About These Companies

Rapt Therapeutics (NASDAQ:RAPT) Receives $21.57 Average PT from Analysts

August 20 at 2:11 AM | americanbankingnews.com

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet

August 18, 2025 | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Moderate Buy" from Analysts

August 18, 2025 | marketbeat.com

Rapt Therapeutics price target raised to $9 from $8 at UBS

August 12, 2025 | msn.com

Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross

August 12, 2025 | zacks.com

HC Wainwright Issues Optimistic Forecast for RAPT Earnings

August 12, 2025 | americanbankingnews.com

HC Wainwright Issues Positive Forecast for RAPT Earnings

August 11, 2025 | marketbeat.com

Rapt Therapeutics (NASDAQ:RAPT) Rating Lowered to Sell at Wall Street Zen

August 10, 2025 | marketbeat.com

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Rapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

August 1, 2025 | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded by JPMorgan Chase & Co. to "Neutral" Rating

July 31, 2025 | marketbeat.com

RAPT Therapeutics Unveils Plans for RPT904 Development

July 30, 2025 | theglobeandmail.com

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

July 30, 2025 | msn.com

JP Morgan Upgrades RAPT Therapeutics (RAPT)

July 30, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

July 26, 2025 | marketbeat.com

Q2 Earnings Forecast for RAPT Issued By Lifesci Capital

July 25, 2025 | marketbeat.com

LifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform Recommendation

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci Capital

July 23, 2025 | marketbeat.com

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Hold" from Analysts

July 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD, MDWD, RAPT, and NLTX Company Descriptions

MediWound NASDAQ:MDWD

$17.60 +0.21 (+1.21%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.58 -0.02 (-0.11%)

As of 08/22/2025 04:04 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Neoleukin Therapeutics NASDAQ:NLTX

$19.75 +0.14 (+0.71%)

As of 08/21/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Prelude Therapeutics NASDAQ:PRLD

$1.24 +0.14 (+12.73%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+1.21%)

As of 08/22/2025 07:59 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Rapt Therapeutics NASDAQ:RAPT

$11.31 +0.59 (+5.50%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$11.32 +0.00 (+0.04%)

As of 08/22/2025 07:15 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time